Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

328 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Phase I study of pazopanib plus TH-302 in advanced solid tumors.
Riedel RF, Meadows KL, Lee PH, Morse MA, Uronis HE, Blobe GC, George DJ, Crawford J, Niedzwiecki D, Rushing CN, Arrowood CC, Hurwitz HI. Riedel RF, et al. Among authors: niedzwiecki d. Cancer Chemother Pharmacol. 2017 Mar;79(3):611-619. doi: 10.1007/s00280-017-3256-2. Epub 2017 Feb 25. Cancer Chemother Pharmacol. 2017. PMID: 28238078 Clinical Trial.
A phase I study of gemcitabine + dasatinib (gd) or gemcitabine + dasatinib + cetuximab (GDC) in refractory solid tumors.
Mettu NB, Niedzwiecki D, Rushing C, Nixon AB, Jia J, Haley S, Honeycutt W, Hurwitz H, Bendell JC, Uronis H. Mettu NB, et al. Among authors: niedzwiecki d. Cancer Chemother Pharmacol. 2019 Jun;83(6):1025-1035. doi: 10.1007/s00280-019-03805-6. Epub 2019 Mar 20. Cancer Chemother Pharmacol. 2019. PMID: 30895346 Free PMC article. Clinical Trial.
A phase Ib study of the combination regorafenib with PF-03446962 in patients with refractory metastatic colorectal cancer (REGAL-1 trial).
Clarke JM, Blobe GC, Strickler JH, Uronis HE, Zafar SY, Morse M, Dropkin E, Howard L, O'Neill M, Rushing CN, Niedzwiecki D, Watson H, Bolch E, Arrowood C, Liu Y, Nixon AB, Hurwitz HI. Clarke JM, et al. Among authors: niedzwiecki d. Cancer Chemother Pharmacol. 2019 Oct;84(4):909-917. doi: 10.1007/s00280-019-03916-0. Epub 2019 Aug 23. Cancer Chemother Pharmacol. 2019. PMID: 31444620 Free PMC article. Clinical Trial.
A phase Ib study of capecitabine and ziv-aflibercept followed by a phase II single-arm expansion cohort in chemotherapy refractory metastatic colorectal cancer.
Strickler JH, Rushing CN, Niedzwiecki D, McLeod A, Altomare I, Uronis HE, Hsu SD, Zafar SY, Morse MA, Chang DZ, Wells JL, Blackwell KL, Marcom PK, Arrowood C, Bolch E, Haley S, Rangwala FA, Hatch AJ, Nixon AB, Hurwitz HI. Strickler JH, et al. Among authors: niedzwiecki d. BMC Cancer. 2019 Nov 1;19(1):1032. doi: 10.1186/s12885-019-6234-8. BMC Cancer. 2019. PMID: 31675952 Free PMC article. Clinical Trial.
Long-term survival of patients with stage III colon cancer treated with VRP-CEA(6D), an alphavirus vector that increases the CD8+ effector memory T cell to Treg ratio.
Crosby EJ, Hobeika AC, Niedzwiecki D, Rushing C, Hsu D, Berglund P, Smith J, Osada T, Gwin Iii WR, Hartman ZC, Morse MA, Lyerly HK. Crosby EJ, et al. Among authors: niedzwiecki d. J Immunother Cancer. 2020 Nov;8(2):e001662. doi: 10.1136/jitc-2020-001662. J Immunother Cancer. 2020. PMID: 33177177 Free PMC article.
Cabozantinib and Panitumumab for RAS Wild-Type Metastatic Colorectal Cancer.
Strickler JH, Rushing CN, Uronis HE, Morse MA, Niedzwiecki D, Blobe GC, Moyer AN, Bolch E, Webb R, Haley S, Hatch AJ, Altomare IP, Sherrill GB, Chang DZ, Wells JL, Hsu SD, Jia J, Zafar SY, Nixon AB, Hurwitz HI. Strickler JH, et al. Among authors: niedzwiecki d. Oncologist. 2021 Jun;26(6):465-e917. doi: 10.1002/onco.13678. Epub 2021 Feb 9. Oncologist. 2021. PMID: 33469991 Free PMC article. Clinical Trial.
328 results